SOUTH SAN FRANCISCO, Calif., Aug. 21, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the BioCentury and Thomson Reuters 19 th Annual Newsmakers in the Biotech Industry 2012 Conference in New York on Friday, September 7 at 11:00 a.m. ET (8:00 a.m. PT).
Donald J. Santel, Chief Executive Officer of Hyperion, will provide a company overview. To access the live webcast and subsequent archived recording, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm.
About Hyperion TherapeuticsHyperion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Hyperion Therapeutics is developing Ravicti™ (glycerol phenylbutyrate) for two orphan indications: urea cycle disorders and hepatic encephalopathy.
CONTACT: Shari Annes, Investor Relations Cell: 650 888 0902 firstname.lastname@example.org